Overview

Pilot E2 for Hypogonadal Women With CFBD

Status:
Withdrawn
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
The study is a prospective, double blinded, placebo controlled, randomized study to evaluate the effects of daily oral estrogen supplements on bone health, sexual and reproductive health, quality of life and markers of inflammation and lung function when given to hypogonadal women with Cystic Fibrosis related Bone Disease (CFBD).
Phase:
Phase 4
Details
Lead Sponsor:
Emory University
Treatments:
Estradiol
Estradiol 17 beta-cypionate
Estradiol 3-benzoate
Estradiol valerate
Polyestradiol phosphate